Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Genmab A/S ADR (GMAB)

Genmab A/S ADR (GMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,389,268
  • Shares Outstanding, K 642,384
  • Annual Sales, $ 3,121 M
  • Annual Income, $ 1,137 M
  • EBIT $ 1,316 M
  • EBITDA $ 1,376 M
  • 60-Month Beta 0.90
  • Price/Sales 6.59
  • Price/Cash Flow 21.12
  • Price/Book 3.57

Options Overview Details

View History
  • Implied Volatility 48.19% (-15.88%)
  • Historical Volatility 22.65%
  • IV Percentile 40%
  • IV Rank 26.87%
  • IV High 93.64% on 02/12/25
  • IV Low 31.49% on 08/28/25
  • Expected Move (DTE 12) 2.72 (8.57%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 274
  • Volume Avg (30-Day) 294
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 4,275
  • Open Int (30-Day) 3,456
  • Expected Range 29.02 to 34.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.45
  • Number of Estimates 7
  • High Estimate 0.56
  • Low Estimate 0.36
  • Prior Year 0.57
  • Growth Rate Est. (year over year) -21.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.15 +12.75%
on 11/06/25
32.48 -2.28%
on 11/28/25
+2.55 (+8.74%)
since 11/05/25
3-Month
27.14 +16.95%
on 09/08/25
33.65 -5.68%
on 10/16/25
+4.20 (+15.25%)
since 09/05/25
52-Week
17.24 +84.11%
on 04/09/25
33.65 -5.68%
on 10/16/25
+9.89 (+45.26%)
since 12/05/24

Most Recent Stories

More News
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R 2 ) resulted in statistically significant and clinically...

GMAB : 31.74 (-0.87%)
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

New two- and three-year EPCORE ® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in patients with DLBCL and FL ...

GMAB : 31.74 (-0.87%)
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

Company Announcement EPKINLY plus rituximab and lenalidomide (EPKINLY + R 2 ) is the first and only bispecific-based...

GMAB : 31.74 (-0.87%)
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

More than 20 abstracts, including seven oral presentations, highlight advancements from the epcoritamab development program supporting the expanded clinical profile and potential of epcoritamab for a broader...

GMAB : 31.74 (-0.87%)
Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Merus N.V....

GMAB : 31.74 (-0.87%)
MRUS : 96.14 (-0.08%)
Targeted Cell Therapies and Precision Degraders Drive $404B Cancer Market Expansion

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Scientists engineered invisible immune cells in October 2025 that hide from rejection while destroying tumors[1],...

IOVA : 2.20 (unch)
GMAB : 31.74 (-0.87%)
NRIX : 18.09 (+0.39%)
GTBP : 0.6094 (-3.24%)
SLS : 1.7400 (unch)
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S ® ) 100 mg/m 2 demonstrated 50% confirmed objective response rate (ORR),...

GMAB : 31.74 (-0.87%)
Truist Financial Remains a Buy on Genmab (GMAB)

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Genmab today. The company’s shares closed yesterday at $32.75.Elevate Your Investing Strategy: Take advantage of TipRanks Premium...

GMAB : 31.74 (-0.87%)
Deutsche Bank Remains a Buy on Genmab A/S (0MGB)

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Genmab A/S today and set a price target of DKK2,000.00. The company’s shares closed last Friday at DKK2,079.33.Elevate Your Investing...

GMAB : 31.74 (-0.87%)
Genmab A/S (0MGB) Receives a Buy from UBS

UBS analyst Xian Deng maintained a Buy rating on Genmab A/S today and set a price target of DKK2,700.00. The company’s shares closed last Friday at DKK2,079.33.Elevate Your Investing Strategy: Take advantage...

GMAB : 31.74 (-0.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 32.71
2nd Resistance Point 32.42
1st Resistance Point 32.08
Last Price 31.74
1st Support Level 31.45
2nd Support Level 31.16
3rd Support Level 30.82

See More

52-Week High 33.65
Last Price 31.74
Fibonacci 61.8% 27.38
Fibonacci 50% 25.44
Fibonacci 38.2% 23.51
52-Week Low 17.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar